Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2017-08-23 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-June 2017 for Alligator Bioscience AB. It contains comprehensive financial statements, management commentary, business updates, and key performance indicators. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. H1 2017
2017-08-23 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report January-June 2017' and contains comprehensive financial data, including income statements, cash flow summaries, and detailed business performance analysis for the specified period. It is not a mere announcement (RPA) or a certification (RNS), but the actual interim financial report. Therefore, it falls under the 'Interim / Quarterly Report' category. H1 2017
2017-08-23 English
Aptevo Therapeutics och Alligator Bioscience inleder CTA-förberedande aktiviteter för den bispecifika immunonkologiska antikroppen ALG.APV-527
Regulatory Filings Classification · 1% confidence The document is a press release from two biotech companies (Alligator Bioscience and Aptevo Therapeutics) announcing that they have initiated CMC activities in preparation for a future CTA (Clinical Trial Application) submission for their drug candidate ALG.APV-527. This type of announcement, detailing progress in drug development, collaboration updates, and future regulatory steps, is characteristic of general corporate news releases in the pharmaceutical/biotech sector. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general announcement about corporate activity and progress, and does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory/corporate announcement category, RNS, as it is a public disclosure required under market regulations (mentioned via reference to EU Market Abuse Regulation). Given the content is a detailed update on a specific project milestone rather than just a notice that a report is attached (which would be RPA), RNS is the best fit for a significant corporate development announcement.
2017-08-17 Swedish
Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527
Regulatory Filings Classification · 1% confidence The document is a press release announcing the commencement of IND-enabling development activities for a new bispecific immunotherapy candidate (ALG.APV-527) between two biotechnology companies. It details scientific progress, management commentary, and includes standard boilerplate sections like 'About' sections and a 'Safe Harbor Statement'. Crucially, the Safe Harbor Statement references filings with the SEC, including the 'most recent Annual Report on Form 10-K' and subsequent 'Form 10-Q and current reports on Form 8-K'. Since this document is a press release announcing operational progress and does not appear to be a formal regulatory filing like a 10-K, 10-Q, or a specific event report (like DIV, DIRS, or CT), it falls best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it discusses development milestones, not financial results.
2017-08-17 English
Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy
Regulatory Filings Classification · 1% confidence The document is a press release dated July 21, 2017, announcing a strategic partnership between two biotechnology companies (Aptevo Therapeutics and Alligator Bioscience) to co-develop a novel bispecific antibody for immunotherapy. This type of announcement details a business development, partnership, or strategic agreement, often related to financing, R&D collaboration, or future capital structure implications, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital change (CAP/SHA). Since it describes a significant business transaction and collaboration agreement, it most closely aligns with an announcement regarding corporate activity or financing/development strategy. Given the options, 'Capital/Financing Update' (CAP) is plausible if the agreement involves immediate funding terms, but 'Regulatory Filings' (RNS) is often used for general press releases announcing material business events that don't fit other specific categories, especially when the text is a standard press release format. However, the core of the document is announcing a joint development agreement and sharing future costs/ownership, which strongly suggests a strategic business development. In the context of financial filings, major partnership announcements are often categorized broadly. Since there is no specific category for 'Business Development' or 'Partnership Announcement', and it is not a formal regulatory report, RNS (Regulatory Filings - general/miscellaneous) is the safest fallback, although CAP could be argued if the focus was purely on the financial commitment. Given the nature of the announcement (co-development agreement), it is a material event announcement. I will classify it as RNS as it is a general press release announcing a material business event that doesn't fit the highly specific financial report codes.
2017-07-21 English
Aptevo Therapeutics och Alligator Bioscience inleder samutveckling av bispecifik antikropp för tumörriktad immunterapi
Regulatory Filings Classification · 1% confidence The document is a press release dated July 21, 2017, announcing a strategic partnership between Aptevo Therapeutics and Alligator Bioscience to co-develop a bispecific antibody (ALG.APV-527) for cancer immunotherapy. It details the terms of the agreement, the mechanism of action (4-1BB activation), and future development plans. This type of announcement, detailing a significant business development, partnership, or strategic agreement, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate action categories (like DIV, SHA, POS). It is a general corporate announcement regarding business strategy and development. Given the options, the most appropriate classification for a significant, non-standard regulatory announcement that doesn't fit elsewhere is the general 'Regulatory Filings' fallback category (RNS), although 'Capital/Financing Update' (CAP) could be considered if the partnership involved immediate, large-scale financing, which is not the primary focus here. Since it is a press release announcing a major business deal, RNS (Regulatory Filings/General Announcement) is the best fit as a catch-all for significant corporate news not covered by other specific codes.
2017-07-21 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.